Cranial base abnormalities in osteogenesis imperfecta: phenotypic and genotypic determinants.
Cranial base abnormalities are an important complication of osteogenesis imperfecta (OI), a hereditary bone fragility disorder that in most patients is caused by mutations affecting collagen type I. To elucidate which clinical characteristics are associated with the occurrence of cranial base abnormalities in OI, we compared cephalometric results of 187 OI patients (median age 12.0 years, range 3.4 to 47 years; 96 female) with those of 191 healthy subjects and related findings to clinical descriptors of the disease. Overall, 41 patients (22%) had at least one unambiguously abnormal skull base measure. Multivariate logistic regression analysis in patients with OI types I, III, and IV (n = 169) revealed that height Z-score [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.43-0.66, p < .001]--but not age, gender, scleral hue, lumbar spine areal bone mineral density, or a history of bisphosphonate treatment--was a significant independent determinant of skull base abnormalities. Among patients with a height Z-score below -3, 48% had a skull base abnormality regardless of whether they had received bisphosphonate treatment in the first year of life or not. Genotype-phenotype correlations were evaluated in patients with detectable mutations in COL1A1 or COL1A2, the genes coding for collagen type I (n = 140). Skull base abnormalities were present in 6% of patients with haploinsufficiency (frameshift or nonsense) mutations, in 43% of patients with helical glycine substitutions caused by COL1A1 mutations, in 32% of patients with helical glycine substitutions owing to COL1A2 mutations, and in 17% of patients with splice-site mutations affecting either COL1A1 or COL1A2. However, multivariate logistic regression analysis showed that height Z-score but not the type of collagen type I mutation was independently associated with the prevalence of skull base abnormalities. In conclusion, this study shows that clinical severity of OI, as expressed by the height Z-score, was the strongest predictor of skull base abnormalities. We did not find evidence for the hypothesis that bisphosphonate treatment protects against skull base abnormalities.
Cheung
Moira S
MS
Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada.
Arponen
Heidi
H
Roughley
Peter
P
Azouz
Michel E
ME
Glorieux
Francis H
FH
Waltimo-Sirén
Janna
J
Rauch
Frank
F
D000293:Adolescent; D001842:Bone and Bones; D002648:Child; D003094:Collagen / Q000235:genetics; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D000090602:Collagen Type I, alpha 1 Chain; D003720:Densitometry / Q000379:methods; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D009154:Mutation; D010013:Osteogenesis Imperfecta / Q000150:complications* / Q000503:physiopathology*; D010641:Phenotype; D010985:Platybasia / Q000503:physiopathology; D012044:Regression Analysis; D012886:Skull / Q000002:abnormalities*
D024042:Collagen Type I; D000090602:Collagen Type I, alpha 1 Chain; D003094:Collagen